- Aptar Pharma has acquired the clinical trial materials manufacturing operations of Mod3 Pharma from SWK Holdings.
- The deal enhances Aptar’s early-stage drug development services, especially for orally inhaled and nasal drug products.
Aptar Pharma has acquired the clinical trial materials manufacturing capabilities of Mod3 Pharma, formerly known as Enteris Biopharma, from SWK Holdings. The acquisition supports Aptar’s strategy to expand its services for early-stage drug development by offering formulation and fill-finish capabilities for Phase 1 and 2 clinical trials.
The transaction builds on an existing collaboration between Aptar and Mod3 Pharma, specifically in serving customers with cGMP fill and finish services for orally inhaled and nasal drug products (OINDPs). This acquisition addresses the growing demand in the market for agile and high-quality clinical trial material supply and enhances Aptar’s broader offering in drug delivery solutions.
Through the deal, Aptar gains an FDA-inspected manufacturing facility in Boonton, New Jersey. The site includes cGMP cleanrooms, suites for high-potency active pharmaceutical ingredients (APIs), biologics capabilities, and advanced fill-finish technologies. These facilities complement Aptar’s portfolio of drug delivery systems.
The integration supports the broader adoption of Aptar’s proprietary devices in early-phase clinical trials, with an initial focus on OINDPs and potential future expansion into dermal, ophthalmic, injectable, and packaging applications.
“Our vision at Aptar Pharma is clear: From formulation to patient,” said Gael Touya, President of Aptar Pharma. “By integrating Phase 1 and 2 clinical manufacturing capabilities, we’re not just expanding our technical footprint – we’re deepening our commitment to customers seeking a seamless and accelerated path to market.”
